Heartburn controlled with step down to once daily therapy

February 27, 2012
Heartburn controlled with step down to once daily therapy

(HealthDay) -- The majority of gastroesophageal reflux disease (GERD) patients who take twice-daily proton pump inhibitor (PPI) therapy, are able to successfully step down to management of heartburn with a daily dose of dexlansoprazole modified release (MR), according to a study published in the March issue of Clinical Gastroenterology and Hepatology.

Ronnie Fass, M.D., of the Southern Arizona VA Healthcare System in Tucson, and associates conducted a multicenter, single-blind study of 142 patients with GERD to determine if twice-daily PPI therapy for more than eight weeks could be phased down successfully to 30 mg once-daily dexlansoprazole MR and what the impact would be on health-related quality of life (QOL). Patients recorded heartburn in electronic diaries; heartburn was considered well-controlled if patients had an average of one symptom or fewer per week during the last four weeks of treatment. GERD-related symptoms and QOL were assessed using the Patient Assessment of Upper (PAGI) Symptom Severity Index and the PAGI-QOL, respectively.

The researchers found that, following step down from PPI therapy, heartburn remained well controlled in 125 patients (88 percent), and these patients were able to maintain their QOL and GERD-related symptom severity.

"Step-down management of GERD patients who have obtained heartburn symptom control on twice-daily dosing should be considered to reduce costs, possibly improve compliance, and reduce the risk of side effects associated with high-dose PPI use," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Takeda, which funded the study and manufactures dexlansoprazole.

Explore further: Modern treatments for GERD effective at achieving long-term remission for most patients

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Recommended for you

Researcher making headway in fighting migraines

December 5, 2016

A study by a UT Dallas researcher has revealed new information about a potential chemical causing pain hypersensitivity in migraines, which is the third most common disease in the world.

Zika in fetal brain tissue responds to a popular antibiotic

November 30, 2016

Working in the lab, UC San Francisco researchers have identified fetal brain tissue cells that are targeted by the Zika virus and determined that azithromycin, a common antibiotic regarded as safe for use during pregnancy, ...

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.